Fresh From the Bench: Latest Precedential Patent Cases
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Inguran, LLC v. ABS Global, Inc., Appeal No. 2022-1385 (Fed. Cir. July 5, 2023)
In its only precedential patent opinion this week, the Federal Circuit held that a lawsuit was not precluded by res judicata based on an earlier judgment. The case turned on whether a judgment for an ongoing royalty of direct infringement claims was res judicata as to a later infringement case alleging induced infringement by the same party of the same claims. The Court held that it was not.
The case involved a long-running dispute relating to bull semen. Specifically, the patents in suit concern technology for creating small tubes or “straws” of bull semen that are predominantly either male or female sperm cells. Having a greater likelihood of genetically male or female sperm is beneficial to livestock breeders, dairy farmers, and beef farmers, who rely on artificial insemination of their herds to increase fertility rates.
Editors:
Nika Aldrich, Shareholder, Schwabe, Williamson & Wyatt, P.C.
Jason Wrubleski, Shareholder
More insights
The Prosecution Data Most IP Attorneys Never Look At
Most prosecution strategy is set before anyone looks at who is actually examining the application. What is sitting there unused Every examiner has a history: allowance rate, average number of office actions, how often an interview changes the outcome. None…
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…